|Bid||47.54 x 1200|
|Ask||47.62 x 800|
|Day's Range||46.95 - 47.90|
|52 Week Range||33.43 - 62.75|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.90|
EMERYVILLE, Calif., Feb. 20, 2019 -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr,.
After the opioid crisis exploded and his company's painkiller was slammed by Massachusetts state officials, Zogenix Inc. CEO Stephen Farr knew the Emeryville drug developer needed to pivot — and fast. The company's done just that: It submitted applications last week to the Food and Drug Administration and the European Medicines Agency, asking the drug regulators to approve its drug, Fintepla, to treat seizures related to a rare form of epilepsy called Dravet syndrome. An answer from the FDA is expected later this year and from European regulators in early 2020.
Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) and submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for FINTEPLA (ZX008, low-dose fenfluramine) for the treatment of seizures associated with Dravet syndrome.
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. We often see insiders buying up shares in Read More...
The awards were made on February 1, 2019 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. The inducement awards consist of options to purchase an aggregate of 28,400 shares of Zogenix common stock. The options have a ten-year term and an exercise price equal to $42.82, the fair market value of Zogenix common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).
NEW YORK, Jan. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Steve Farr has been the CEO of Zogenix, Inc. (NASDAQ:ZGNX) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
The brokerage predicted that GW Pharmaceuticals’ cannabis-derived drug Epidiolex will eventually surpass $1 billion in annual sales.
Eversept Partners is a New York-based hedge fund that focuses on investing in companies from the healthcare sector. It was founded by its current portfolio manager Mr. Kamran Moghtaderi, who previously worked as an Analyst and Portfolio Manager at Apis Capital Advisors, LLC. Mr. Moghtaderi’s investment experience is much more extensive than this, as prior […]
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
If you’re interested in Zogenix Inc (NASDAQ:ZGNX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
A post-hoc exploration of the clinical meaningfulness of seizure control from the first pivotal Phase 3 trial (Study 1) will also be presented. The data will be presented at the 72nd American Epilepsy Society (AES) Annual Meeting in New Orleans.
EMERYVILLE, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced results from a post-hoc analysis of its investigational drug, FINTEPLA® (ZX008), on caregiver-reported everyday executive function in children and young adults with Dravet syndrome, who participated in the Company’s first pivotal Phase 3 clinical trial, Study 1. Full posters can be found on www.zogenix.com here.
Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that it will host an Investor Update Lunch on FINTEPLA® (ZX008) on Monday, December 3, 2018, from 12:00 PM to 2:00 PM CST, at the American Epilepsy Society (AES) 2018 Annual Meeting in New Orleans. Zogenix's management team will provide a summary of the information from other Company-sponsored posters to be presented at AES, as well as a general corporate update. Zogenix is committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases.
EMERYVILLE, Calif., Nov. 27, 2018 -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS).
Full Results from Second Pivotal Phase 3 Trial of FINTEPLA® (ZX008) in Dravet Syndrome (Study 1504) New Long-Term Efficacy and Safety Data from Open-Label Extension Trial.
The Emeryville, California-based company said it had a loss of $1.08 per share. Losses, adjusted for non-recurring costs, were 93 cents per share. The results fell short of Wall Street expectations. The ...